Minovia Therapeutics Archives

Home / Posts tagged Minovia Therapeutics

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved engraftment and bone marrow reconstitution potential of patient derived hematopoietic stem cells In vitro data also demonstrated improved ability to differentiate to erythroid cells, supporting potential for improvement in biomarkers of anemia HAIFA, Israel, Sept. 26 (Korea Bizwire) [...]

Minovia Therapeutics Appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as Board Member

TIRAT HACARMEL, Israel, Jan. 5 (Korea Bizwire) – Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment. Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and hematological disorders associated with mitochondrial dysfunction. As a [...]

Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023

WOBURN, Mass. and HAIFA, Israel, Jan. 3 (Korea Bizwire) — Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the Company will be presenting at the Biotech Showcase on Tuesday, January 10, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Time: 9:45 AM PST Track: Franciscan C (Ballroom Level) Biotech [...]

Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases

WOBURN, Mass. and HAIFA, Israel, Dec. 21 (Korea Bizwire) — Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the findings of the first clinical use of mitochondrial augmentation therapy (MAT) platform to treat pediatric patients with primary mitochondrial diseases have been published in Science Translational Medicine. The study was conducted in collaboration with global leaders [...]